| Property | Value |
|---|---|
| Protein Name | Methyl-CpG Binding Protein 2 |
| Gene | MECP2 |
| UniProt ID | P51608 |
| Molecular Weight | ~53 kDa (486 aa) |
| Subcellular Localization | Nucleus (chromatin-associated) |
| Protein Family | Methyl-CpG binding domain (MBD) family |
| Tissue Expression | High in brain (neurons), moderate in other tissues |
Methyl-CpG Binding Protein 2 (MECP2) is a nuclear protein encoded by the MECP2 gene that functions as a transcriptional regulator and chromatin modifier[1]. It was first identified as a protein that binds methylated DNA and mediates transcriptional repression. MECP2 is essential for normal brain development and function—loss-of-function mutations cause Rett syndrome, a severe neurodevelopmental disorder, while MECP2 duplication causes a distinct neurodevelopmental syndrome.
MECP2 is expressed predominantly in neurons, where it regulates the expression of thousands of genes involved in synaptic plasticity, neuronal connectivity, and brain function. Beyond transcriptional regulation, MECP2 also has roles in RNA splicing, chromatin remodeling, and DNA repair. The protein is often described as a "genome guardian" for neurons, with critical functions in maintaining neuronal identity and function[2].
MECP2 contains several distinct structural domains that enable its diverse functions[2:1]:
Methyl-CpG Binding Domain (MBD, residues 89-167): The ~80 amino acid domain that recognizes methylated CpG dinucleotides. This domain contains a conserved fold that inserts into the major groove of methylated DNA.
Transcriptional Repression Domain (TRD, residues 206-309): Mediates interaction with corepressor complexes including Sin3A and HDAC. This domain recruits histone deacetylases to silence gene expression.
N-terminal domain (residues 1-88): Contains a conserved motif that can bind to DNA regardless of methylation status (AT-rich DNA binding domain).
C-terminal domain (residues 310-486): Functions in protein-protein interactions and contains a PWWP-like domain for chromatin binding.
MECP2 function is regulated by multiple modifications:
| Modification | Sites | Functional Impact |
|---|---|---|
| Phosphorylation | S80, S164, S421 | Alters DNA binding, activity |
| Acetylation | K382 | Affects protein stability |
| SUMOylation | K389 | Modulates transcriptional function |
| Methylation | R294 | Regulates interaction with HDACs |
These modifications create a dynamic regulatory system where MECP2 function can be modulated in response to neuronal activity.
MECP2 is a global transcriptional regulator in neurons[2:2]:
The balance between activation and repression depends on context, neuronal activity, and post-translational modifications.
MECP2 is critical for normal brain development:
MECP2 plays essential roles in synaptic plasticity[3]:
As a chromatin-associated protein, MECP2:
MECP2 mutations are the primary cause of Rett syndrome[1:1]:
Genetic Basis:
Pathological Mechanisms:
Clinical Features:
Conversely, MECP2 duplication causes a distinct disorder:
MECP2 has complex relationships with AD:
Emerging evidence links MECP2 to PD:
Several therapeutic strategies are under investigation[3:1]:
| Strategy | Approach | Status |
|---|---|---|
| Gene therapy | AAV-MECP2 delivery | Preclinical/Phase 1 |
| Protein replacement | Recombinant MECP2 | Research |
| Activation | Increase MECP2 expression | Discovery |
| Symptomatic | Target downstream pathways | Various stages |
Amir RE, et al. Rett syndrome is caused by mutations in MECP2. Nature Genetics. 1999. ↩︎ ↩︎
Chahrour M, et al. MeCP2 activates and represses transcription. Science. 2008. ↩︎ ↩︎ ↩︎
Katz DM, et al. Rett syndrome mechanisms and therapeutic targets. Nature Reviews Neurology. 2012. ↩︎ ↩︎